Outsourced Pharma White Papers
-
Understanding FDA Guidance For Pediatric Oncology Studies
2/17/2022
Learn how the Research to Accelerate Cures and Equity (RACE) for Children Act aims to improve and expand treatment options for pediatric cancer patients.
-
Making The Right Decisions Upstream To Ensure Downstream Success
5/12/2022
Explore the latest strategies and technologies to develop a comprehensive, optimal approach to assay development and product characterization.
-
Switching Delivery Formats: A Lifecycle Management Strategy For Sterile Injectables
12/9/2022
Switching delivery formats can be an effective strategy to enhance the lifecycle of your drug. Gain insight into the benefits and challenges of transferring a therapeutic compound from one aseptic injectable format to another.
-
Components Of An Effective Disinfectant Prequalification Strategy
1/24/2022
Cleaning procedures designed specifically to destroy microbial contaminants that may be present are an important component of any microbial control strategy.
-
Tech Transfers: Optimize Success And Mitigating Risk
10/4/2022
Gain direction for ensuring successful technology transfers by understanding how to identify common challenges and find case-based solutions and best practices for overcoming them.
-
Assessing End-To-End Drug Development Partnerships
1/24/2022
As drug development becomes increasingly expensive and complex, pharma companies are relying on CDMOs. Consider the opportunities and challenges of end-to-end arrangements.
-
Taking Charge Of Your Stability Program
10/5/2022
Learn how consolidating stability testing with a single partner offers improved efficiency, reduced risk, and more.
-
Rational Design And Development Of Long-Acting Injectable Dosage Forms
1/26/2022
The increasing prevalence of chronic disorders, growing demand for self-administration, and the increasing demand for minimally invasive surgeries have fueled the growth of the LAI drug delivery market.
-
Innovative Formulation Technologies By 505(b)(2) Regulatory Pathway
1/24/2022
Revitalization of older marketed drugs using innovative drug delivery technologies can provide new marketing exclusivity and patent protection, offering an effective tool for product life cycle management.
-
Are End-To-End CDMO Partnerships The Solution To Drug Development And Manufacturing Upheaval?
1/24/2022
Growing complexity and risks in drug development and supply have implications for outsourcing models. See how to structure and manage CDMO partnerships for a future with uncertainty and disruption.